MEIP
MEI Pharma, Inc.
Set alert
3.07 USD 0.00 0.00%
2.85 Day range 3.25
2.30 52-week range 6.39
- YTD
- +132.58%
- 1 year
- +132.58%
- Open
- 2.89
- Prev close
- 3.07
- Mkt cap
- 15.72M
- Vol
- 3.97M
- Avg vol
- 46.70K
- EPS
- -6.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.85
- High
- 3.25
- Forward P/E
- -0.64
- Beta
- 0.71
- Short ratio
- 0.94
- Inst. own
- 41.04%
- Dividend
- 0.00
- Ex-div date
- Nov 15, 2023
- Earnings
- Feb 11, 2025
- 50-d avg
- 2.83
- 200-d avg
- 3.10
- 1y target
- 0.00
Key statistics
- Market cap
- 15.72M
- Enterprise value
- -17.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.64
- PEG ratio
- 0.00
- Price / sales
- 0.24
- Price / book
- 0.48
- EPS (TTM)
- -6.99
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 27.23%
- Revenue (TTM)
- 65.30M
- Revenue growth
- -100.00%
- Free cash flow
- 12.76M
- Total cash
- 38.34M
- Total debt
- 0
- Return on equity
- 61.68%
- Shares outstanding
- 6.66M
- Short % of float
- 1.48%
- 50-day average
- 2.83
- 200-day average
- 3.10
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 2 0 buy · 2 hold · 0 sell
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate 0.00.
Financials — quick view
MEIP Revenue — quarterly 0
MEIP Net income — quarterly -2.57M
MEIP EPS — quarterly -0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -1.20 | — | — |
| Sep 19, 2024 | Jun 1, 2024 | -1.48 | -1.13 | +0.35 | +23.65% |
| May 9, 2024 | Mar 1, 2024 | -1.38 | -1.37 | +0.01 | +0.72% |
| Feb 13, 2024 | Dec 1, 2023 | -1.46 | -1.66 | -0.20 | -13.70% |
| Nov 9, 2023 | Sep 1, 2023 | -1.47 | 8.46 | +9.93 | +675.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2024 | Laidlaw & Co. | down | Buy | Hold |
| Apr 12, 2024 | Stifel | main | Hold | Hold |
| Feb 14, 2024 | Stifel | main | Hold | Hold |
| Sep 27, 2023 | Stifel | main | Hold | Hold |
| May 23, 2023 | Brookline Capital | main | Buy | Buy |
| May 12, 2023 | Stifel | main | Hold | Hold |
About MEI Pharma, Inc.
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- meipharma.com
News
- MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
- 12 Health Care Stocks Moving In Friday's After-Market Session
- BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
- MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
- Why Is MEI Pharma Stock Soaring On Friday?
- MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
- MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
Your note
Sign in to keep a note on MEIP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANSON FUNDS MANAGEMENT L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 19, 2023 | 0 |
| BALTIC CHARLES V III | Director | Purchase | Feb 27, 2023 | 111,100 |
| FLYNN JAMES P | Director | Stock Award(Grant) | May 15, 2024 | 7,900 |
| WOOD STEVEN D | Director | Stock Award(Grant) | May 16, 2024 | 72,092 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 16.41% | 1,093,183 | 2.58M | Sep 29, 2024 |
| Cable Car Capital LLC | 9.18% | 611,440 | 1.44M | Sep 29, 2024 |
| Vanguard Group Inc | 5.79% | 385,728 | 910.32K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.07% | 137,646 | 324.84K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.99% | 132,362 | 312.37K | Sep 29, 2024 |
| Blackrock Inc. | 1.01% | 67,260 | 158.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.02% | 201,106 | 474.61K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 79,554 | 187.75K | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 0.92% | 61,621 | 145.43K | Jul 30, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.55% | 36,960 | 87.22K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 35,708 | 84.27K | Oct 30, 2024 |
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.45% | 30,000 | 70.80K | Sep 29, 2024 |